MetaCap

Kalaris Therapeutics (KLRS) vs Genenta Science S.p.A. (SAEN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Kalaris Therapeutics is the larger company by market cap ($30.5 million vs $24.5 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

KLRS-37.56%SAEN-47.19%
+21%-15%-50%
Nov 3, 20261 yearNov 20, 2026
KLRS-47.11%SAEN-23.70%
+2%-24%-49%
Nov 2, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

KLRS versus SAEN key metrics
MetricKLRSSAEN
Share price$1.28$0.5074
Market cap$30.47M$24.47M
1-day change-5.19%-9.39%
YTD return-84.83%—
1-year return-81.74%—
5-year return-99.70%—
EPS (TTM)$-1.84$-0.37
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-43.44M—
52-week high$11.88$2.58
52-week low$1.25$0.50
Distance from 52-week high-89.23%-80.33%
Analyst consensusstrong_buy—
Avg. price target upside+1361.72%—
Average volume77.37K85.01K
Shares outstanding23.80M48.22M
Employees209
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Kalaris Therapeutics

KLRS stock →

Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 20 employees

About Genenta Science S.p.A.

SAEN stock →

Genenta Science S.p.A. operates as a strategic consolidator that focuses on acquiring ownership of privately held companies operating in Italian national-security-regulated sectors.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 9 employees

KLRS vs SAEN FAQ

Which is bigger, Kalaris Therapeutics or Genenta Science S.p.A.?

Kalaris Therapeutics (KLRS) is larger, with a market capitalization of $30.47M compared with $24.47M for Genenta Science S.p.A. (SAEN).

Are Kalaris Therapeutics and Genenta Science S.p.A. in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons